A biotech slow liquidation

Combined with a higher quality business

I have been on a winning streak with biotech stocks in the past few years. I actually remember thinking 2 years ago that I would not even look at them, but when a sector gets cheap it is just too tempting not to, and I am not regretting it so far.

The stock I have today is a slow selling off of a lower quality low growth business to focus more on the higher quality business. The sale proceeds from selling its low growth medical devices business could easily surpass the company’s current enterprise value based on sales made in the past year. I think this stock is a relatively straight forward double with multiple catalysts to unlock value.